ScripBioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou
ScripInitial public offerings (IPOs) for innovative, drug-focused biotechs have remained elusive in the Chinese mainland well into the second half of 2024, since the country’s top securities regulator put
Pink SheetChina has broken its own record for the number of clinical trial registrations in one year, with the total surging by 26% in 2023 to reach 4,300, notes a new annual report from the country's Center fo